Abstract: The present disclosure relates to ionizable lipidoid compounds comprising an anisamide moiety, and lipid nanoparticles (LNPs) comprising the same. In certain embodiments, the LNP selectively binds to at least one sigma receptor. In certain embodiments, the LNP specifically targets a cell of interest (e.g., a cell expressing a sigma receptor, fibroblast, cancer cell, stromal cell, and epithelial cell, inter alia). In another aspect, the present disclosure provides methods for in vivo delivery of therapeutic agents to treat, prevent, and/or ameliorate diseases and/or disorders, including but not limited to fibrosis and cancer.
Type:
Application
Filed:
December 6, 2022
Publication date:
April 24, 2025
Applicant:
The Trustees Of The University Of Pennsylvania
Abstract: Disclosed herein is a method for the delivery of prenatal therapeutics, enzyme replacement therapy, or gene therapy to a fetus in need thereof. The method comprises introducing ionizable lipid nanoparticles (LNPs) nanoparticles comprising a therapeutic mRNA composition into the circulation of the fetus in need of treatment such that the ionizable LNPs deliver the therapeutic mRNA composition.
Abstract: The present invention relates to a method and device for preparing biodegradable polymer microspheres, and an injection formulation preparation method using same and, more specifically, to a parallel-type continuous reaction membrane emulsification method and device which can not only adjust the size but also mass produce biodegradable polymer microspheres maintaining a uniform size while maintaining the spherical shape, and a method for preparing a microsphere injection same. According to the formulation composition comprising parallel-type continuous reaction membrane emulsification method and device for preparing biodegradable polymer microspheres according to one embodiment of the present invention, since the particle size of the biodegradable polymer microspheres can easily be adjusted, and also spherical particles of a uniform size can easily be prepared, the method and device are suitable for mass production.
Abstract: The present invention relates to a solid oral dosage form for sustained release in the lower gastrointestinal tract, comprising antibodies or functional fragments thereof in a depot layer (2) covering an inert core unit (1), a sustained release layer (3) covering the depot layer, and a delayed release layer (4) covering the sustained release layer, preferably prepared by drug layering; an oral multiparticulate drug delivery system comprising a plurality of the solid oral dosage forms; and the use of the solid oral dosage form in the targeted local treatment in the lower gastrointestinal tract of a patient.
Type:
Application
Filed:
October 2, 2024
Publication date:
April 24, 2025
Applicant:
Tillotts Pharma AG
Inventors:
Roberto Carlos BRAVO GONZALEZ, Ramon VOGLER
Abstract: The present invention relates to a pharmaceutical composition that efficiently increases the absorption rate of a large physiologically active substance in the body; and specifically to a pharmaceutical composition comprising: (i) a large physiologically active substance; and (ii) excipient A comprising a bile acid derivative or (iii) excipient B comprising a compound having CYP450 inhibition, an antioxidant effect, or gastrointestinal enzyme activity inhibitory effect, and a method for preparing same.
Abstract: This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
Type:
Application
Filed:
September 26, 2024
Publication date:
April 24, 2025
Inventors:
Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
Abstract: The purpose of the present invention is to provide tablets which contain magnesium oxide particles capable of achieving both of the reduction in friability and the reduction in a capping occurrence rate as a main component. Provided are tablets each of which comprises granules comprising both of magnesium oxide particles and an internal additive and an external additive, in which at least cellulose and/or a cellulose derivative is contained as the internal additive and the external additive and the [cellulose and/or a cellulose derivative contained as the internal additive]:[cellulose and/or a cellulose derivative contained as the external additive] ratio falls within the range from 75:25 to 10:90 by mass.
Abstract: A method for preparing a migrasome by suppressing the cell volume-regulatory function and then produce a migrasome derived from the cell and a method for preparing a delivery system including a migrasome.
Type:
Application
Filed:
December 26, 2024
Publication date:
April 24, 2025
Applicant:
BEIJING MIGRASOME THERAPEUTICS LIMITED
Inventors:
Li YU, Dongju WANG, Chen DAI, Moye JIA, Shuo WANG, Tianlun DING, Takami SHO, Yi ZHENG
Abstract: Provided are ionizable lipids containing a piperazine moiety, as well as lipid nanoparticles that can be formed using the ionizable lipids for use in delivering nucleic acids and other therapeutic agents to specific cell types.
Type:
Application
Filed:
December 20, 2022
Publication date:
April 24, 2025
Inventors:
James Dahlman, Marine Z.C. Hatit, Huanzhen Ni
Abstract: Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is an LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Type:
Application
Filed:
October 2, 2024
Publication date:
April 24, 2025
Inventors:
Priya Prakash Karmali, Steven Tanis, Yanjie Bao
Abstract: Patches configured to hold an oncogenic cargo and deliver the cargo in a controlled manner to a predetermined location of a specified tissue are disclosed. As one example, a patch can comprise a base layer configured to adhere to a predetermined location of a tissue and a hydrogel layer. The hydrogel layer can comprise a plurality of microchannels that are configured to store and release a gene-modifying vector over a time period and in a quantity sufficient to produce a somatic cell tumor through manipulation of the genome of somatic cells at the predetermined location.
Type:
Application
Filed:
February 1, 2023
Publication date:
April 24, 2025
Applicant:
The Board of Trustees of the University of Illinois
Inventors:
Hyunjoon Kong, Byoungsoo Kim, Lawrence B. Schook, Kyle Schachtschneider, Lobna Elkhadragy, Maximillian Carlino
Abstract: The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.
Abstract: The present invention relates to the use of an improved curcuminoids composition for improving and/or maintaining functional performance and/or relieving, treating, decreasing and/or preventing muscle soreness in a subject during and/or after exercise.
Type:
Application
Filed:
June 15, 2022
Publication date:
April 24, 2025
Inventors:
Julie LAVAL, Pascale Elizabeth Reneé FANÇA-BERTHON, Sandra NARANJO MODAD
Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
Type:
Application
Filed:
October 2, 2024
Publication date:
April 24, 2025
Inventors:
Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
Abstract: Provided herein are methods for reducing p-tau, Abeta40, Abeta42, and/or the p-tau/Abeta+2 ratio in subjects using ALZ-801. Also provided are methods of treating conditions associated with elevated levels of p-tau, elevated levels of Abeta40, elevated levels of Abeta42, and/or an elevated p-tau/Abeta42 ratio.
Type:
Application
Filed:
February 7, 2023
Publication date:
April 24, 2025
Inventors:
Susan Abushakra, John Hey, Martin Tolar
Abstract: Compositions for use in the prevention and/or treatment of at least one adverse effect of a chemotherapy in the treatment of cancer are disclosed. The compositions have N-acetylcysteine (NAC) and vitamin B12 and/or a combination of vitamins B1, B2 and B3. Methods of treatment of chemo-induced nociceptive and/or neuropathic pain by administering such compositions are also disclosed.
Type:
Application
Filed:
January 27, 2023
Publication date:
April 24, 2025
Applicants:
PRONUTRI, UNIVERSITE COTE D'AZUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.
Abstract: The present invention relates to a stable, parenteral formulations of naproxen sodium. The formulation further relates to liquid formulations comprising naproxen sodium, cyclodextrin and optionally other pharmaceutically acceptable excipients selected from pH modifying agents, chelating agents and tonicity agents. Also relates to the process of preparing the same. These formulations are stable when stored at recommended storage conditions and can be manufactured using simple manufacturing procedure. These compositions can be used to treat pain, particularly when quicker onset of action is desired. Further the present invention also relates to the parenteral formulations of naproxen in combination with additional active ingredients.
Abstract: Disclosed are decalcification compositions for the treatment and prevention of cardiovascular disease and methods of administering such compositions to patients.
Abstract: Described are room temperature stable gabapentin powders that can be readily reconstituted in water for dosing as an oral solution. The gabapentin powder formulations have improved chemical stability, palatability, portability, storage, and ease of administration, as well as fast reconstitution time, and prolonged product shelf life. The gabapentin powder formulations comprise gabapentin, a sugar alcohol, one or more artificial sweeteners and, optionally, a flavoring agent.
Type:
Application
Filed:
August 30, 2022
Publication date:
April 24, 2025
Inventors:
Samuel A. TESTINO, Dongwei GUO, Benjamin BURGESS
Abstract: A composition containing 3-hydroxyanthanilic acid (3HAA) and a compound that alters iron homeostasis (an iron chelator or an iron supplement). The combination may be used as a new antibiotic drug. Combining 3HAA with iron chelation may have the dual benefit of inhibiting pathogen growth while repressing the pathological hyperinflammatory response in septic individuals. The combination may be effective at preserving food by preventing bacterial growth.
Abstract: The invention relates to a composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection and a bacterial bone infection in a patient, the composition comprising ribose and the amino acids glycine, alanine and glutamine in aqueous solution, the method comprising orally administering the composition to the patient additionally treated with an antibiotic.
Abstract: The present invention provides methods and kits a) for preventing and/or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of ?-difluoromethylornithine (DFMO), either as a monotherapy or in combination with one or more other drugs.
Abstract: The gut microbiota produces a wide variety of metabolites, which interact with intestinal cells by modulating either gene transcription or post-translational modifications of gut proteins. The effect of gut commensal bacteria on SUMOylation, an essential ubiquitin-like modification in intestinal physiology, remains however unknown. Here, the inventors show that branched chain fatty acids (BCFAs) increase protein SUMOylation in different intestinal cell lines. They demonstrated that the hyperSUMOylation induced by BCFAs inhibits the activation of the NF-?B pathway by blocking the degradation of the inhibitory factor I?B? in response to TNF?. This results in a decrease in pro-inflammatory cytokines expression as well as a decrease in intestinal epithelial permeability in response to TNF?.
Type:
Application
Filed:
August 30, 2022
Publication date:
April 24, 2025
Inventors:
David RIBET, Pierre DECHELOTTE, Chaima EZZINE
Abstract: The present invention relates to treating SARS-CoV-2 infection by concurrent administration of different treatment supplementation through anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The lower doses of the proposed treatment modalities in the present invention denoted anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The higher doses of the proposed treatment modalities in the present invention promoted the release the CD4+ and CD8+ T cell, increasing the phagocytosis activity for viral clearance of SARS-CoV-2 infection. The proposed treatment modalities in the present invention allow the maturation of antibodies against natural SARS-CoV-2 infection.
Abstract: The present invention relates to a shelf-stable veterinary formulation for promoting eye health and/or comfort in a companion animal consisting of a palatable ductile chewable veterinary composition comprising an omega-3 fatty acid oil; at least one anti-inflammatory plant extract; and at least one carotenoid. The present invention also relates to methods of promoting eye health and/or comfort in a companion animal using such compositions.
Type:
Application
Filed:
October 23, 2024
Publication date:
April 24, 2025
Inventors:
Albert Jernigan Swann, Carina Norrene Gassman
Abstract: Methods of treating cancers or precancerous conditions and treating cancers in partial or complete remission are disclosed. The methods involve topical application of topical contact sensitizers, such as squaric acid dibutylester.
Abstract: The present disclosure relates to methods for the treatment or prevention of headache, such as migraine and related headache. The methods include administering compositions comprising at least one compound capable of elevating ketone body concentrations in a subject in need thereof (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of headache, such as migraine and related headache. In one embodiment, the composition includes medium chain triglycerides (MCT), such as tricaprylin.
Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.
Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.
Abstract: The disclosure belongs to the technical field of medicine, and specifically discloses a traditional Chinese medicine compound preparation for tumors and application thereof. The traditional Chinese medicine compound preparation includes dimethylarsenic acid, indirubin and cordycepin in a concentration ratio of (1-20):(1-10):(1-40). The traditional Chinese medicine compound preparation of the disclosure can be used for treating kinds of tumors, including leukemia, gastric cancer, lung cancer, glioma, papillary thyroid carcinoma, growth hormone adenoma, pituitary adenoma, myeloma, and other malignant tumors. The traditional Chinese medicine compound preparation has significant treatment effect, high safety, and good development prospects.
Type:
Application
Filed:
October 16, 2024
Publication date:
April 24, 2025
Inventors:
Aihua Liang, Jingzhuo Tian, Chenyue Liu
Abstract: The present invention relates to a composition comprising orlistat and acarbose for use in reducing rebound effect in obese or overweight subjects.
Type:
Application
Filed:
May 20, 2022
Publication date:
April 24, 2025
Applicant:
Empros Pharma AB
Inventors:
Jan Stefan Persson GRUDÉN, Anders FORSLUND, Ulf HOLMBÄCK, Jan Arvid SÖDERHALL, Göran ALDERBORN
Abstract: This application discloses the medicinal application of dimyricetin-yl-diselenide in tumors. Experiments have confirmed that dimyricetin-yl-diselenide has the potential for tumor treatment.
Abstract: This application discloses the use of dimyricetin-yl-diselenide in the preparation of a pharmaceutical composition for preventing, alleviating and/or treating cardiovascular diseases, and for preventing and/or treating atherosclerosis.
Abstract: Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, in treating a subject suffering from myelodysplastic syndromes (MDS), and hi slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).
Type:
Application
Filed:
May 16, 2022
Publication date:
April 24, 2025
Inventors:
Daniel Kremer, Sida Shao, Peter G. Schultz, Michael J. Bollong
Abstract: The present disclosure relates to 3,4-methylenedioxymethamphetamine (MDMA) or a pharmaceutically acceptable salt and/or solvate thereof, pharmaceutical compositions and dosage forms containing these particles, and methods of using pharmaceutical compositions and dosage forms containing these particles to treat subjects suffering from disorders of the central nervous system.
Type:
Application
Filed:
December 30, 2024
Publication date:
April 24, 2025
Inventors:
Jay Nair, Berra Yazar-Klosinski, Julian Northen, Arul Balasundaram, Linda Hakes, John Briston
Abstract: The present disclosure relates to 3,4-methylenedioxymethamphetamine (MDMA) or a pharmaceutically acceptable salt and/or solvate thereof, pharmaceutical compositions and dosage forms containing these particles, and methods of using pharmaceutical compositions and dosage forms containing these particles to treat subjects suffering from disorders of the central nervous system.
Type:
Application
Filed:
December 30, 2024
Publication date:
April 24, 2025
Inventors:
Jay Nair, Berra Yazar-Klosinski, Julian Northen, Arul Balasundaram, Linda Hakes, John Briston
Abstract: The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating myotonia.
Abstract: The disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of PF-07104091, as a monotherapy or in combination with an endocrine therapy agent and/or a CDK4/6 inhibitor.
Abstract: A composition and a use of the composition in the preparation of a medicament for treating eye diseases. The composition includes 0.5-1.5% by weight of a muscarinic acetylcholine receptor M3 agonist; 0.005-0.5% by weight of naphazoline, a pharmaceutically acceptable salt thereof or a combination thereof; and 0.1-1% by weight of ketorolac tromethamine. While enhancing the effect of a muscarinic acetylcholine receptor M3 agonist such as a pilocarpine active ingredient in treating presbyopia, the composition effectively significantly reduces or even eliminates side effects caused by the pilocarpine active ingredient.
Type:
Application
Filed:
December 27, 2022
Publication date:
April 24, 2025
Inventors:
Jidong LIU, Qiang YANG, Dan LI, Yang JIN, Lili ZHAO
Abstract: A method of inhibiting viral replication of a virus in an individual comprising administering an effective amount of a drug nanosuspension combined with a surfactant, wherein the drug nanosuspension combined with the surfactant is delivered to the individual's lungs. Preferably, the drug is a nanosuspension delivered to the individual's lungs through inhalation.
Type:
Application
Filed:
February 10, 2023
Publication date:
April 24, 2025
Inventors:
Oreola Donini, Axel Lehrer, Daiqin Chen, Jung Soo Suk, Joe DiCostanzo
Abstract: Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Type:
Application
Filed:
December 23, 2024
Publication date:
April 24, 2025
Inventors:
Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
Abstract: The present disclosure relates to combinations of a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.
Abstract: The disclosure provides methods of treating opioid use disorder in a human by rapid induction with monthly injectable extended release buprenorphine, and to rapid induction dosage regimens for treating opioid use disorder. The methods provide increased treatment retention compared to standard of care methods.
Type:
Application
Filed:
October 18, 2024
Publication date:
April 24, 2025
Inventors:
Christian A. HEIDBREDER, Frank GRAY, Celine M. LAFFONT, Robert L. DOBBINS
Abstract: The present disclosure describes methods and compositions for treating CDKL5 deficiency disorder (CDD), a severe neurodevelopmental disorder characterized by early-onset, treatment-resistant epilepsy and global developmental impairment. The invention describes the use of monoamine oxidase inhibitors (MAO-Is), particularly MAO-A inhibitors such as harmine, for reducing convulsive seizure frequency in patients suffering from CDD. The MAO-Is may be administered alone or in combination with one or more anti-epileptic drugs (AEDs). The disclosed methods further include treatment strategies targeting CDKL5 paralogues to modulate neuronal signaling pathways and synaptic function. In vivo and in vitro studies demonstrate the efficacy of MAO-Is in upregulating CDKL5 protein expression and restoring synaptic homeostasis, offering a novel therapeutic approach for treating CDKL5-related epilepsy and other symptoms associated with the disorder.
Abstract: An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.
Abstract: The subject matter disclosed herein is generally directed to treating cancers sensitive to phosphate dysregulation with inhibitors of inositol pyrophosphate (PP-InsP) synthesis, in particular, inhibitors of inositol hexakisphosphate kinases IP6Ks.